Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …

Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the
diagnosis and treatment of adults with AML based on clinical trials that have led to …

Background Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2)
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …

Conventional therapy for acute myeloid leukemia is composed of remission induction with
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …

Abstract The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …

Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for
diagnostic subtyping, prognosis, and patient management. However, cytogenetic …

Approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor
mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact …

Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …